Global Drug Discovery Informatics Market

Drug Discovery Informatics Market Size, Share, Growth Analysis, By Workflow(Discovery Informatics and Development Informatics), By Mode(Outsourced, and In-house), By Services(Sequence Analysis Platforms, Molecular Modeling, Docking, Clinical Trial Data Management), By Region - Industry Forecast 2025-2032


Report ID: SQMIG35I2209 | Region: Global | Published Date: March, 2024
Pages: 219 | Tables: 89 | Figures: 76

Drug Discovery Informatics Market Insights

Drug Discovery Informatics Market size was valued at USD 3.29 Billion in 2023 and is poised to grow from USD 3.66 Billion in 2024 to USD 0 Billion by 2032, growing at a CAGR of 11.30% during the forecast period (2025-2032).

The drug discovery informatics market is expected to rise in the coming years as a result of advances in high-performance computing and online services, increased usage of in-silico modeling techniques, a growing volume of drug development data, and rising demand for innovative pharmaceutical moieties. The introduction of improved drug discovery information technologies is expected to heighten industry competition. Certara, Inc., for example, released version 20 of its Simcyp Physiologically-based Pharmacokinetic (PBPK) Simulation’s platform in January 2021. The new models aid in assessing and analyzing medication activity throughout pregnancy and breastfeeding.

Furthermore, it assists clients in making key decisions regarding optimizing drug safety and efficacy profiles. Companies are also growing implementing informatics technologies to reduce the lengthy drug research schedule. Curve Therapeutics Ltd., for example, will handle its biologically encoded Microcycle platform in 2021 using the CDD Vault platform. It is a widely used hosted platform for applications in pharmaceutical, biotechnology, & academic institutes for the secure and frictionless sharing of data in real-time, encouraging collaborative discoveries.

In addition, more rapid Covid-19 medication discovery around the globe is adding to market growth. For example, in order to provide quick solutions, scientists used virtual screening using drugs from the DrugBank to target viral proteins in and human ACE2 receptors. These investigations relied on silico techniques for screening small compounds with the potential to be used in drug discovery against Covid-19.

Similarly, companies are developing a variety of digital services and solutions to aid in the various stages of drug development for Covid-19. for example, the IBM visual molecular explorer platform investigated a subset of the produced compounds targeting the coronavirus (SARS-CoV-2). The explorer's open-source sharing of AI-generated artifacts aided in the early stages of optimal medication design.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Drug Discovery Informatics Market size was valued at USD 3.29 Billion in 2023 and is poised to grow from USD 3.66 Billion in 2024 to USD 0 Billion by 2032, growing at a CAGR of 11.30% during the forecast period (2025-2032).

The competitive landscape of the global drug discovery informatics market is characterized by the presence of several companies offering a range of software solutions, platforms, and services for various stages of the drug discovery process. These companies compete based on factors such as product features, performance, scalability, customer support, and pricing. For example, Charles River Laboratories International, Inc. partnered with Deciphex. The Patholytix Preclinical platform from Deciphex will aid in increasing pathologist productivity by getting data to clients more quickly. This aided in the expansion of the company's market portfolio. 'Accelrys (Biovia)', 'Schrödinger', 'Genedata', 'OpenEye Scientific Software', 'Certara', 'Dotmatics', 'Collaborative Drug Discovery (CDD)', 'Optibrium', 'Chemical Computing Group (CCG)', 'IBM Watson Health', 'PerkinElmer', 'BioSolveIT', 'Entelos', 'Dassault Systèmes Biovia', 'XtalPi Inc.', 'OpenText', 'Benchling', 'MedChemica Ltd.', 'ChemAxon', 'BioSymetrics Inc.'

The growing prevalence of various diseases and the need for effective treatment options have led to an increased demand for novel drugs. Drug discovery informatics plays a crucial role in accelerating the drug discovery process by enabling efficient data analysis, predictive modeling, and virtual screening, thus driving market growth.

Increasing Adoption of Artificial Intelligence (AI) and Machine Learning (ML): AI and ML technologies are being increasingly integrated into drug discovery informatics to enhance efficiency and accuracy. These technologies enable advanced data analysis, predictive modeling, and virtual screening, leading to accelerated drug discovery processes and improved success rates.

North America held the greatest market share of 39.30% in 2022; growth in the region may be ascribed to a number of factors, including an elevated prevalence of infectious illnesses, rapid adoption of new and advanced R&D technologies, and the presence of major companies. Furthermore, businesses in the region are concentrating on joint ventures and research partnerships that are expected to fuel market expansion in the future years.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Drug Discovery Informatics Market

Report ID: SQMIG35I2209

$5,300
BUY NOW GET FREE SAMPLE